These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

927 related articles for article (PubMed ID: 34670506)

  • 1. Pembrolizumab plus lenvatinib with or without hepatic arterial infusion chemotherapy in selected populations of patients with treatment-naive unresectable hepatocellular carcinoma exhibiting PD-L1 staining: a multicenter retrospective study.
    Chen S; Xu B; Wu Z; Wang P; Yu W; Liu Z; Huang X; Wu Y; Li T; Guo W
    BMC Cancer; 2021 Oct; 21(1):1126. PubMed ID: 34670506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lenvatinib plus TACE with or without pembrolizumab for the treatment of initially unresectable hepatocellular carcinoma harbouring PD-L1 expression: a retrospective study.
    Chen S; Wu Z; Shi F; Mai Q; Wang L; Wang F; Zhuang W; Chen X; Chen H; Xu B; Lai J; Guo W
    J Cancer Res Clin Oncol; 2022 Aug; 148(8):2115-2125. PubMed ID: 34453221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatic arterial infusion chemotherapy, lenvatinib plus programmed cell death protein-1 inhibitors: A promising treatment approach for high-burden hepatocellular carcinoma.
    Fu S; Xu Y; Mao Y; He M; Chen Z; Huang S; Li D; Lv Y; Wu J
    Cancer Med; 2024 May; 13(9):e7105. PubMed ID: 38686567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors for advanced hepatocellular carcinoma with macrovascular invasion.
    Zhang Y; Zhang H; Xu H; Wang Y; Feng L; Yi F
    World J Surg Oncol; 2024 May; 22(1):122. PubMed ID: 38711095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toripalimab Combined With Hepatic Arterial Infusion Chemotherapy Versus Lenvatinib for Advanced Hepatocellular Carcinoma.
    Xu YJ; Lai ZC; He MK; Bu XY; Chen HW; Zhou YM; Xu L; Wei W; Zhang YJ; Chen MS; Guo RP; Shi M; Li QJ
    Technol Cancer Res Treat; 2021; 20():15330338211063848. PubMed ID: 34898313
    [No Abstract]   [Full Text] [Related]  

  • 6. Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Transarterial Chemoembolization for Large Hepatocellular Carcinoma: A Randomized Phase III Trial.
    Li QJ; He MK; Chen HW; Fang WQ; Zhou YM; Xu L; Wei W; Zhang YJ; Guo Y; Guo RP; Chen MS; Shi M
    J Clin Oncol; 2022 Jan; 40(2):150-160. PubMed ID: 34648352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of lenvatinib plus durvalumab combined with hepatic arterial infusion chemotherapy for unresectable intrahepatic cholangiocarcinoma.
    Zhao R; Zhou J; Miao Z; Xiong X; Wei W; Li S; Guo R
    Front Immunol; 2024; 15():1397827. PubMed ID: 38799453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-L1 inhibitor versus PD-1 inhibitor plus bevacizumab with transvascular intervention in unresectable hepatocellular carcinoma.
    Huang Z; Chen T; Li W; Qiu J; Liu S; Wu Z; Li B; Yuan Y; He W
    Clin Exp Med; 2024 Jun; 24(1):138. PubMed ID: 38940944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
    He M; Li Q; Zou R; Shen J; Fang W; Tan G; Zhou Y; Wu X; Xu L; Wei W; Le Y; Zhou Z; Zhao M; Guo Y; Guo R; Chen M; Shi M
    JAMA Oncol; 2019 Jul; 5(7):953-960. PubMed ID: 31070690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Lyu N; Kong Y; Mu L; Lin Y; Li J; Liu Y; Zhang Z; Zheng L; Deng H; Li S; Xie Q; Guo R; Shi M; Xu L; Cai X; Wu P; Zhao M
    J Hepatol; 2018 Jul; 69(1):60-69. PubMed ID: 29471013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma.
    Finn RS; Ikeda M; Zhu AX; Sung MW; Baron AD; Kudo M; Okusaka T; Kobayashi M; Kumada H; Kaneko S; Pracht M; Mamontov K; Meyer T; Kubota T; Dutcus CE; Saito K; Siegel AB; Dubrovsky L; Mody K; Llovet JM
    J Clin Oncol; 2020 Sep; 38(26):2960-2970. PubMed ID: 32716739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction therapy with hepatic arterial infusion chemotherapy enhances the efficacy of lenvatinib and pd1 inhibitors in treating hepatocellular carcinoma patients with portal vein tumor thrombosis.
    Fu Y; Peng W; Zhang W; Yang Z; Hu Z; Pang Y; Hu D; Chen J; Wang J; Zhou Z; Xu L; Chen M; Zhang Y
    J Gastroenterol; 2023 Apr; 58(4):413-424. PubMed ID: 36894804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatic arterial infusion chemotherapy with anti-angiogenesis agents and immune checkpoint inhibitors for unresectable hepatocellular carcinoma and meta-analysis.
    Cao YZ; Zheng GL; Zhang TQ; Shao HY; Pan JY; Huang ZL; Zuo MX
    World J Gastroenterol; 2024 Jan; 30(4):318-331. PubMed ID: 38313229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of tislelizumab plus lenvatinib as first-line treatment in patients with unresectable hepatocellular carcinoma: a multicenter, single-arm, phase 2 trial.
    Xu L; Chen J; Liu C; Song X; Zhang Y; Zhao H; Yan S; Jia W; Wu Z; Guo Y; Yang J; Gong W; Ma Y; Yang X; Gao Z; Zhang N; Zheng X; Li M; Su D; Chen M
    BMC Med; 2024 Apr; 22(1):172. PubMed ID: 38650037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world efficiency of lenvatinib plus PD-1 blockades in advanced hepatocellular carcinoma: an exploration for expanded indications.
    Sun X; Zhang Q; Mei J; Yang Z; Chen M; Liang T
    BMC Cancer; 2022 Mar; 22(1):293. PubMed ID: 35305593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TACE combined Lenvatinib plus Camrelizumab versus TACE alone in efficacy and safety for unresectable hepatocellular carcinoma: a propensity score-matching study.
    Tang Z; Bai T; Wei T; Wang X; Chen J; Ye J; Li S; Wei M; Li X; Lin Y; Tang J; Li L; Wu F
    BMC Cancer; 2024 Jun; 24(1):717. PubMed ID: 38862932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma: a prospective non-randomized study.
    He MK; Le Y; Li QJ; Yu ZS; Li SH; Wei W; Guo RP; Shi M
    Chin J Cancer; 2017 Oct; 36(1):83. PubMed ID: 29061175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatic arterial infusion chemotherapy combined with anti-PD-1/PD-L1 immunotherapy and molecularly targeted agents for advanced hepatocellular carcinoma: a real world study.
    Zhang W; Zhang K; Liu C; Gao W; Si T; Zou Q; Guo Z; Yang X; Li M; Liu D; Mu H; Li H; Yu H; Xing W
    Front Immunol; 2023; 14():1127349. PubMed ID: 37180098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.
    Motzer R; Alekseev B; Rha SY; Porta C; Eto M; Powles T; Grünwald V; Hutson TE; Kopyltsov E; Méndez-Vidal MJ; Kozlov V; Alyasova A; Hong SH; Kapoor A; Alonso Gordoa T; Merchan JR; Winquist E; Maroto P; Goh JC; Kim M; Gurney H; Patel V; Peer A; Procopio G; Takagi T; Melichar B; Rolland F; De Giorgi U; Wong S; Bedke J; Schmidinger M; Dutcus CE; Smith AD; Dutta L; Mody K; Perini RF; Xing D; Choueiri TK;
    N Engl J Med; 2021 Apr; 384(14):1289-1300. PubMed ID: 33616314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lenvatinib, toripalimab plus hepatic arterial infusion chemotherapy in patients with high-risk advanced hepatocellular carcinoma: A biomolecular exploratory, phase II trial.
    Lai Z; He M; Bu X; Xu Y; Huang Y; Wen D; Li Q; Xu L; Zhang Y; Wei W; Chen M; Kan A; Shi M
    Eur J Cancer; 2022 Oct; 174():68-77. PubMed ID: 35981413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 47.